Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

The standard treatment for Triple Negative Breast Cancer (TNBC) patients is cytotoxic chemotherapy, but it is restricted since the duration of response is usually short. Blocking the PD-1/PD-L1 pathway through monoclonal antibodies (mAbs) appears to be a promising therapeutic strategy for TNBC patie...

Full description

Bibliographic Details
Main Authors: Estefanía Paula Juliá, Analía Amante, María Betina Pampena, José Mordoh, Estrella Mariel Levy
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Immunology
Subjects:
Avelumab
triple negative breast cancer (TNBC)
PD-L1
ADCC
IL-2
IL-15
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02140/full

Similar Items

Similar Items